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Introduction
Solid tumors consist of cancer cells embedded in a network 
of non-malignant cells and extracellular matrix, referred to as 
tumor stroma. Cancer cell-intrinsic alterations, including antigen 
loss, antigen-processing, and presentation defects, and upregu-
lation of negative co-stimulatory molecules, are major obstacles 
to anti-cancer immunotherapy.1 In addition, cancer cells secrete 
chemokines and cytokines to establish paracrine stimulatory 
loops with stromal cells, which allow antigenic cancer cells to 
escape immune destruction.2-4 Pre-clinical and clinical data have 
revealed that such paracrine stimulatory loops between the can-
cer cell and the microenvironment induce tumorigenic processes 
including angiogenesis, invasion, and metastasis.5 Although 
tumor stroma contributes to immune-suppressive networks, 
which restrict the effectiveness of certain cancer therapies,6-8 stro-
mal cells are non-malignant and generally genetically stable and 
therefore less likely to escape chemo-, radiation-, and/or immu-
notherapy,9 thus making tumor stroma an attractive target for 
new anti-cancer therapeutic strategies.10
Cancer cells in solid tumors sensitize the surrounding stroma 
to T cell recognition through the constant release of antigens. 
Stromal cells can pick up cancer antigens, present antigenic epi-
topes on their surface MHC molecules, and become targets for 
antigen-specific T cells.11-13 The source of tumor antigen for stro-
mal loading can be apoptotic or necrotic cancer cells, microvesi-
cles or nanometer-sized exosomes secreted by fully viable cancer 
cells,14-16 or peptides transferred directly via gap junctions.17,18 
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a fluorescence-based, high-resolution imaging approach was used to visualize longitudinally the cellular events 
unfolding during T cell-mediated tumor destruction. The dynamic interplay of T cells, cancer cells, cancer antigen loss 
variants, and stromal cells—all color-coded in vivo—was analyzed in established, solid tumors that had developed 
behind windows implanted on the backs of mice. events could be followed repeatedly within precisely the same tumor 
region—before, during and after adoptive T cell therapy—thereby enabling for the first time a longitudinal in vivo evalu-
ation of protracted events, an analysis not possible with terminal imaging of surgically exposed tumors. T cell infiltration, 
stromal interactions, and vessel destruction, as well as the functional consequences thereof, including the elimination 
of cancer cells and cancer cell variants were studied. Minimal perivascular T cell infiltrates initiated vascular destruction 
inside the tumor mass eventually leading to macroscopic central tumor necrosis. Prolonged engagement of T cells with 
tumor antigen-crosspresenting stromal cells correlated with high IFNγ cytokine release and bystander elimination of 
antigen-negative cancer cells. The high-resolution, longitudinal, in vivo imaging approach described here will help to 
further a better mechanistic understanding of tumor eradication by T cells and other anti-cancer therapies.
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Figure 1. Tumor model for in vivo longitudinal imaging of solid established tumors growing behind skin-fold window chambers. (A) Model of T cell-
recognized tumor antigens presented directly and/or indirectly to 2C transgenic CD8+ T cells. 2C T cells recognize the self-peptide p2Ca presented on 
MHC class I Ld which can only be presented directly. 2C T cells also recognize the synthetic SIyryyGL (SIy) peptide in context of MHC class I Kb. SIy can be 
directly presented by Kb-positive cancer cells as well as cross-presented by antigen-presenting cells (aPC) expressing Kb. (B) Color-coded T cells, cancer 
cells and host stromal cells; T cells express eyFP as transgene, cancer cells are transduced to express Cerulean, and host cells, including tumor stromal 
cells, express Dsred. Numbers indicate excitation/emission wavelengths for fluorescent proteins. (C) Fluorescence intensity of T cells from 2C TCr × eyFP 
transgenic F1 mice. eyFP expression of CD8+ and Vß8.1 double-positive cells was analyzed by flow cytometry; gray line represents the background fluo-
rescence of T cells from 2C TCr transgenic mice lacking the fluorescent transgene. (D) CD11b+ cells isolated from a spleen of Dsred Rag1−/− mice express 
high level of Dsred. CD11b+ splenocytes from a litter mate that does not express the transgene Dsred are used as control (gray line); Dsred expression 
might potentially vary in different types of stromal cells. (E) The MC57 cell line was transduced to express the model tumor antigens SIy-Cerulean or Ld 
and Cerulean. Pro4L was transduced to express SIy-Cerulean. all transduced tumor lines were FaCS-sorted for high expression of Cerulean. The inset 
numbers indicate the mean fluorescence intensity. Untransduced tumor cells are included for comparison (gray lines). (F) Tumor growth and T cell-
mediated eradication of large, established tumors developing behind the dorsal window. a dorsal window and MC57-SIy-Cerulean cancer cells were 
implanted onto the back skin fold of C57Bl/6 Rag−/− mice as described in Methods and Figure S2. By day 21, large established tumors developed behind 
the window. after adoptive transfer of activated, antigen-specific 2C T cells tumors regressed and were eliminated (day 32). (G) Fourteen hours after 
window implantation and MC57-SIy-Cerulean cancer cell transplantation, cancer cells were imaged by confocal microscopy (top picture); to visualize 
pre-established vasculature, 2.000.000 MW fluorescein-conjugated dextran was injected i.v. into the mouse (lower picture); data are representative of 
more than 15 displays of different injection areas, n = 3 mice. Z-stack images were recorded and x-y plane, xz and yz projections are shown to the right 
(z = 220μm). (H) eighteen days later, the same tumor, now large and established, was imaged. The existence of irregular micro-vasculature typical for 
established tumors was visualized by dextran-FITC injection; data are representative of at least 2 mice. 
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Previously, we showed that T-cell mediated eradication of solid 
tumors, including antigen-loss variants (ALV), is successful 
when stroma cross-presents tumor-antigen11,19    . Although we 
previously demonstrated that sensitized stroma could be lysed by 
T cells ex vivo, the question of whether and how the recognition 
of stroma by T cells in vivo promotes the death of cancer cells 
and/or their variants remained unanswered.
In this study, we set out to capture the kinetics of T cell-
mediated tumor destruction and to dissect the dynamic events 
and cellular interactions between cancer cells, T cells and stromal 
cells in solid, established tumors in vivo. Technological advances 
in optical imaging have allowed the observation of some intra-
tumoral immune events, but focused mainly on the visualiza-
tion of T cell-cancer cell interactions.20-27 Furthermore, surgically 
exposed tumors were imaged in previous studies that depended 
on reconstructing a putative sequence of events from observa-
tions of serially sacrificed mice. Caution is needed in interpreting 
these results because of the acute effects of surgery on blood flow, 
and leukocyte infiltration.28-30 Ideally one would like to “revisit” 
the exact same site in a tumor at different time points to better 
understand the interaction of T cells with cancer and stromal 
cells over hours and tissue morphology responses over days or 
even weeks. Thus, in this study our objective was to follow in 
vivo the response of solid tumor tissue to adoptive T cell therapy 
over short and long time frames in single cell resolution. For this, 
we established an experimental system combining the implant-
able tumor window technology31 with a custom-made precision 
holder and an optimized multi-color reporter system to stably 
color-code T cells, cancer cells, including cancer antigenic vari-
ants, and the non-malignant stromal microenvironment in mice 
for the longitudinal observation. Here we report the longitudi-
nal sequence of events unfolding in precise locations within solid 
tumors following T cell transfer and provide novel insights into 
T-cell mediated tumor destruction.
Results
Cancer cells, tumor stroma, and adoptively transferred 
CD8+ T cells express distinct fluorescent reporter proteins for 
in vivo visualization
For our in vivo imaging studies, we used the well-character-
ized 2C TCR-transgenic mouse model. 2C CD8+ T cells rec-
ognize the synthetic SIYRYYGL (SIY) peptide in association 
with the MHC class I molecule Kb. SIY antigen can be directly 
presented by cancer cells expressing SIY or cross-presented by 
antigen-presenting cells (APC) expressing Kb (Fig. 1A). In addi-
tion to recognizing the SIY antigen, 2C T cells also recognize 
Ld, which is an allogeneic MHC class I molecule that presents 
the peptide p2Ca, LSPFPFDL, derived from the house-keep-
ing gene α-ketoglutarate dehydrogenase.32,33 p2Ca cannot be 
Figure 2. Longitudinal visualization of tumor stroma formation. (A) MC57-SIy-Cerulean cells were injected into a Dsred Rag1−/− mouse. Images were 
taken 14h, 4d, and 8d post window and cancer cell implantation. While 14h after window/cancer cell implantation, the site is densely infiltrated with 
round, rapidly moving stromal cells (image corresponds to Video 1), 4–8d later the number of these cells is greatly reduced and many stromal cells 
acquire a stellate and spindle-like shape (image corresponds to Video 2). (B) Tumor growth in color-coded bone-marrow (BM) chimeric mice with 
cerulean-blue tumor cells, Dsred BM-derived host cells, and eyFP-yellow non-BM-derived host cells. Cancer cells mobilize BM-cells and non-BM cells 
for the formation of tumor stroma. Non-BM-derived cells account mainly for tumor vasculature. Data are representative of 3 independent experiments. 
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cross-presented because 2C T cells only recognize it in the con-
text of Ld and not Kb. Thus p2Ca can only be presented by cancer 
cells directly as p2Ca/Ld (Fig. 1A).
To stably color-code cancer cells, T cells and tumor stroma, we 
used fluorescent reporter proteins that (1) differ significantly in 
their peak absorption and emission wavelengths, (2) do not affect 
the functional properties of the cells, (3) are bright and stable, 
and (4) have spectral profiles that are unaltered by environmental 
effects such as pH.34,35 We used the fluorescent reporters EYFP 
(yellow/green) to visualize adoptively transferred transgenic 2C 
T cells, Cerulean (blue) to image cancer cells, and DsRed (red) to 
visualize non-malignant host stromal cells (Fig. 1B).36-38 By com-
bining these fluorescent proteins we could readily distinguish 
each cellular component in the confocal microscopy mode using 
standard filter sets. Compared with single laser multiphoton exci-
tation, the spectral separation of multiple fluorophores benefited 
from excitation multiplexing, and the spatial resolution was 
excellent. As shown in Figure 1C and 2C, CD8+ T cells isolated 
from 2C × EYFP F1 transgenic TCR mice expressed high levels 
of the EYFP protein. To highlight the tumor microenvironment, 
Figure 3. entry, distribution, cytolytic activity, and motility of tumor-specific T cells in tumors after adoptive transfer. (A) and (B) T cells enter the tumor 
as early as 2–3 d after transfer. In vitro activated, tumor-specific 2C eyFP T cells adoptively transferred into a Dsred Rag1−/− mouse bearing a MC57-SIy-
Cerulean tumor extravasate and enter into the tumor tissue at few distinct sites (data are representative of more than 3 independent experiments). 
(C) and (D) 24 h later, T cells do not uniformly distribute within the tumor, but heterogeneously. (E) Fluorescence intensity profiles for Cerulean, eyFP, 
and Dsred were acquired throughout total fields of view (FOV) of Figure 3D. Increased fluorescence intensity indicates accumulation of cell popula-
tions. (F) and (G) Cell-cell interactions during T cell-mediated tumor destruction. 2C eyFP T cells engage with MC57-SIy-Cerulean cancer cells; apoptotic 
membrane blebbing of cancer cells (yellow arrows); enlarged, 3-dimensional, rotated display of the T cell-cancer cell engagement (right). T cells also 
engage with stromal cells [(F), yellow arrows]; image corresponds to Video 4. (H) Perforin is not needed for the rejection of established MC57-SIy 
tumors. In vitro activated 2C Prf−/− or 2C WT T cells were adoptively transferred into MC57-SIy tumor bearing mice (when tumors reached a size of about 
500 mm3 [between days 13 and 17 as indicated by the horizontal bars (┣┫)]. The number of rejected tumors per total number of tumors is indicated. 
Data are pooled from 5 independent experiments. P = 0.026 (2C Prf−/− and 2C WT). (I) 1–2 d after cancer cell elimination T cells remain in microenviron-
ment and stably engage with stromal cells; image corresponds to Video 6. Data are representative of 3 independent experiments (n = 4 mice). (J) 
Comparison of diffusion coefficient and average velocities of T cells in Video 6 (T cells remain arrested) and Video 7 (T cells regain motility ~4 d post 
cancer cell elimination). each dot represents an individual T cell; red lines indicate mean; black bars indicate the time-domain standard deviation (td-
StDev). Data are representative of 2 independent experiments (**P = 0.0064; ***P < 0.0001). 
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we crossed DsRed transgenic mice into the recombination acti-
vating gene 1 (Rag1) knockout background, and DsRed Rag1−/− 
mice (> 8 weeks old) were used as host mice for all our tumor 
transplantation studies, unless otherwise stated. Host cells, 
including antigen-presenting cells such as CD11b+ cells isolated 
from spleens of DsRed Rag1−/− mice showed high expression levels 
of DsRed (Fig. 1D). For the visualization of cancer cells, a ret-
roviral vector pMFG was constructed encoding the trimeric pep-
tide (SIYRYYGL-AAY)
3
 fused to the Cerulean-coding sequence. 
MC57 is a C57BL/6-derived fibrosarcoma and the Pro4L 
tumor cell line was derived from a UV-induced tumor in a C3H 
mouse; both cell lines have been extensively used in our previ-
ously described studies.39 MC57 and Pro4L were transduced to 
express the tumor antigen SIY-Cerulean (MC57-SIY-Cerulean, 
Pro4L-SIY-Cerulean). In addition, MC57 was transduced to 
co-express Ld and Cerulean (MC57-Ld-Cerulean) (Fig. 1E). In 
combination with 2C CTL, this tumor model allowed to study 
3 different scenarios of T cell mediated tumor and/or stromal cell 
interactions: (1) MC57-SIY-Cerulean, in which both cancer and 
stroma are T cell targets, (2) Pro4L-SIY-Cerulean, in which only 
stromal cells cross-presenting SIY antigen are targeted, and (3) 
MC57-Ld-Cerulean, in which only cancer cells are recognized by 
2C CTL (Fig. S1).
Tumor growth and T cell-mediated eradication of large, 
established tumors using a modified dorsal window
In order to longitudinally visualize the microscopic events 
occurring in tumors before, during and after T cell transfer, we 
needed to generate an optical imaging setting that allows cancer 
Figure 4. antigen-dependent stromal engagement of 2C-eyFP CD8+ T cells in Pro4L-SIy-Cerulean tumors (A–D). T cells interact with Dsred-positive 
stromal cells (yellow arrows); scale bar = 75μm. Image corresponds to Video 8. (B) Left panel. Stromal engagement of T cells is antigen-dependent. 
Percentage of T cell/stromal cell engagements in Pro4L-SIy-Cerulean (ag-positive) and Pro4L-Cerulean (ag-negative) tumors. See Methods for further 
details. Right panel, arrest coefficient, (C) average velocities, and (D) representative displacement tracks for 2C T cells in antigen-positive Pro4L-SIy and 
antigen-negative Pro4L control tumors are graphed (scale bar = 50μm). red lines indicate mean; black bars indicate td-StDev. Data are representative 
of 3 experiments and mice, 2 with Pro4L-SIy tumors and 1 with Pro4L. a total of 12 movies (Pro4L-SIy) and 3 movies (Pro4L) were analyzed, 30–150 min 
long. In B and C, each dot represents an individual T cell. P values were obtained with Mann–Whitney analysis for (B–D); ***P < 0.0001. (E) Left panel: 
IFNγ secretion by 2C T cells stimulated with tumor-derived stromal cells or cancer cells. CD11b+ stromal cells were isolated from established antigen-
positive MC57-SIy tumors (or antigen-negative MC57-hgp100 tumors as control) by magnetic separation and co-cultured with peptide-activated 2C T 
cells. Stromal cells were compared with equal numbers of cultured cancer cells expressing the same antigen. Supernatants were harvested after 24 h of 
co-culture and IFNγ was measured by eLISa. Non-stimulated T cells served as negative control (none) and a Data are representative for 4 independent 
experiments. right panel: High in vivo IFNγ levels in solid tumors after adoptive T cell transfer only when cross-presentation is enabled. Rag−/−mice 
with established MC57, MC57-Ld, or MC57-SIy tumors were treated with activated 2C T cells. Three and 6 d after T cell transfer, in vivo IFNγ levels were 
determined in homogenized tissues of individual tumors by eLISa as per manufacturer’s instructions (eBioscience). Bars represent IFNγ levels per gram 
of tumor tissue. Data are representative for 2 experiments with 3 to 5 tumors per group. 
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cells to grow naturally and form large tumors. Therefore, we 
used the modified dorsal window chamber model as previously 
described.31,40,41 We implanted customized titanium window 
frames onto the backs of mice as to sandwich an extended double 
layer of skin. The front epidermal layer of skin was removed in a 
circular area of approximately 1cm in diameter, leaving the rear 
skin layer with its dermis and fascia intact (for technical details, 
see Methods and Fig. S2A). MC57-SIY-Cerulean cancer cells 
were injected between the fascia and dermis of the rear skin layer 
and the area was then covered with a circular glass slide and sta-
bilized by a C-ring (Fig. 1F; Fig. S2A). Fourteen hours later, the 
mouse was placed onto a custom-made adaptor for a motorized 
microscope stage and the injection sites within the window area 
were imaged using confocal laser scanning microscopy at con-
stant ambient temperatures. Deposits of round, cerulean-blue 
cancer cells were visible through the window moments after the 
Figure  5. Longitudinal imaging and quantifica-
tion of vessel integrity, vessel perfusion, and 3D 
vessel volume in solid tumors after adoptive T cell 
transfer. (A) activated 2C T cells were adoptively 
transferred into a Dsred host mice with a 21-d-old 
established solid tumor (95% MC57-SIy eGFP + 5% 
MC57 Cerulean). at indicated time points post T cell 
transfer same tumor area was imaged (scale bar = 
50μm). (B–F) Dsred Rag1−/− mice with established 
MC57-Cerulean or MC57 SIy-Cerulean tumors 
growing behind windows were injected with 
activated 2C eyFP CD8 T cells at day 18 of tumor 
growth. DiD-labeled red blood cells were injected 
intravenously into mice on the day of T cell transfer 
and tumors were imaged in 3D and longitudinally, 
every 12 h, at indicated time points by acquiring 
numerous sets of z-stack volumes. (B) Bright field 
images (top) and maximal projections of z-stacks 
(bottom) of DiD-labeled red blood cells (purple), 
2C eyFP T cells (yellow), MC57-Cerulean (right), 
and MC57 SIy-Cerulean (left) cancer cells (cyan 
blue) at indicated time points post T cell transfer. 
(C) representation of vessel perfusion indexes 
(VPI) generated from time-domain standard devia-
tions (td-StDev) of DiD-intensities throughout 
the entire set of z-stacks. The higher the td-StDev 
values in the DiD channel per pixel, the higher 
the assigned color intensity values in the pseudo-
colored image (option Fire LUT; Fiji). a detailed 
description of the generation of VPI is provided in 
Materials and Methods. VPI is an indirect measure 
of vessel integrity: high td-StDev in the DiD chan-
nel indicates fast blood flow and consequently 
good vessel integrity; low td-StDev results from 
static DiD-rBC reflecting impaired vessel integrity. 
Vessel leakiness/damage is observed in antigen-
positive MC57 SIy tumors, but not in antigen-neg-
ative MC57 tumors after T cell transfer. (D) Vessel 
Perfusion Indexes, and (E) 3D volumetric vessel 
analysis for MC57 and MC57 SIy tumors measured 
over several days post T cell transfer. Calculations 
and methods used to quantify vessel density in 3D 
images are described in Materials and Methods. 
(D) and (E) show averages and StDev from several 
tumor regions followed longitudinally. N of regions 
at each time point is as follows (day, N); for antigen-
positive tumor: (d1,6;d1.5,7;d2,9;d2.5,9;d3,4); for 
control tumor (d1,6;d1.5,5;d2.5,5;d3,4;d3.5,3). a 
second, independent longitudinal experiment 
with another mouse showed similar results. (F) The 
area occupied by cancer cells, T cells and vessels 
was measured for images displayed in Figure 5B. 
The maximum value of area fraction for each chan-
nel was assigned the value of 100% and all subse-
quent values for the specific channel were plotted 
as percent of maximum. 
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placement (Fig. 1G, upper picture). To image the pre-existing 
vasculature in the window at the injection sites, the mouse was 
injected intravenously with a solution of high molecular weight 
fluorescein-labeled dextran. Three-dimensional (3D) reconstruc-
tion analysis revealed that cerulean-blue cancer cells were in very 
close proximity to the preexisting blood vessels of fascia and der-
mis of the back skin fold (Fig. 1G, lower picture). The cancer 
cells continued to grow, and within 3 weeks, a large established 
tumor had formed behind the window (Fig. 1F, left picture). The 
tumor grew with similar growth kinetics as subcutaneous tumors 
(Fig. S2B) and displayed the irregular vascularization with 
abnormal branching patterns typical of established solid tumors 
(Fig. 1H). In vitro activated 2C T cells were adoptively trans-
ferred into the window-tumor-bearing mouse on day 21. The 
MC57-SIY-Cerulean solid tumor regressed and was eliminated 
within 12 d (Fig. 1F, right picture). Thus, the modified dorsal 
window model not only provided an environment for cancer cells 
to form established tumors unimpeded by the dimensions of the 
Figure 6. Visualization of bystander elimination of antigen-loss variants (aLV). (A) To visualize aLV, parental MC57 cells were transduced to express 
Dsred. The inset numbers indicate the mean fluorescence intensity by flow analysis. Parental MC57 is used as control (gray line). (B) Scheme. Model 1: 
antigen-positive MC57-SIy-Cerulean cancer cells are mixed with 5% of MC57-Dsred aLV and transplanted into C57Bl/6 Rag1−/−  mice (n = 3). Model 2: 
antigen-positive MC57-Ld-Cerulean cancer cells are mixed with 5% of MC57-Dsred aLV and transplanted into C57Bl/6 Rag1−/−  mice (n = 2). (C–D) Both 
cell mixtures grow with red aLV homogeneously embedded in the blue, antigen-positive tumor tissue [image 1]. adoptively transferred 2C eyFP T cells 
arrive in the tumors [image 2; 3–4 d post T cell transfer]. While T cells eliminate the blue antigen-positive MC57-SIy-Cerulean and MC57-Ld-Cerulean 
cancer cells, the red aLV are not killed and “red-only areas” emerge [image 3; 4 d post T cell transfer]. While red aLV in the MC57-SIy-Cerulean microenvi-
ronment disappear over time (model 1 [image 4; 6 d post T cell transfer]), aLV in the MC57-Ld Cerulean microenvironment persist and continue to grow 
(model 2 [image 4; 5 d post T cell transfer]). (E) Percent of image occupied by Dsred aLV and blue SIy- or Ld-expressing cancer cells before (left panel; 
corresponding to Figure 6C and D (image 2) or during/after (right panel; corresponding to Figures 6C and D (images 4)) T cell mediated destruction. 
While the presence of aLV in the SIy model significantly decreases, aLV in the Ld-tumor persist and continue to grow. Images were acquired using differ-
ent magnifications and subsequently adjusted digitally to be in the same scale. (F) arrest coefficient, diffusion coefficient and average velocities of 2C 
T cells in the microenvironment of MC57-SIy or MC57-Ld tumors are graphed. red lines indicate mean, black bars indicate td-StDev; ***P < 0.0001; *P = 
0.0122. (G) representative displacement tracks from 2C T cells in MC57-SIy or MC57-Ld tumors (scale bar = 40μm).
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window chamber, but also allowed T cell-mediated destruction 
with similar kinetics compared with window-less MC57-SIY 
cancers growing subcutaneously12 (Fig. S2B).
Visualization of tumor stroma
To visualize the formation of tumor stroma during tumor 
development, windows were implanted onto the backs of DsRed 
Rag1−/− mice and MC57-SIY-Cerulean cancer cells were placed 
as described above. Fourteen hours post implantation we imaged 
the site of cancer cell transplantation through the window. In 
addition to Cerulean-blue cancer cells, high numbers of rapidly 
moving “amoeboid,” round, red host cells were present (Fig. 2A; 
Video 1). These cells, possibly granulocytes and/or monocytes/
macrophages, infiltrated the site in response to pro-inflamma-
tory effects of the window and cancer cell implantation. Over 
the next 4–5 d, the amoeboid host cells diminished and non-
migratory fibroblastoid (stellate or spindle-shaped) red host cells 
accumulated forming a cohesive network (Fig. 2A, correspond-
ing to Video 2). A similar ratio of mobile and sessile cellular stro-
mal elements was present at later time points (day 8) (Video 2), 
and by day 21 stroma and cancer cells together formed a dense 
network including vasculature (Fig. S3A). Window implanta-
tion into DsRed Rag1−/− mice without the injection of cancer cells 
(only PBS solution) also caused the rapid infiltration of amoe-
boid motile host cells; however, no fibroblastoid cells were visible 
at later time points (Fig. S3B), suggesting that malignant cells 
recruited and promoted the accumulation of fibroblastoid cells. 
Similar observations regarding the stromal composition were 
made with Pro4L-SIY-Cerulean tumors (Fig. S3C).
Tumor stroma consists of heterogeneous bone marrow (BM) 
and non-BM derived cell populations and targeting both popula-
tions is crucial for the complete elimination of tumors, including 
cancer variants.11,19 Such stromal cells include immature CD11b+ 
myeloid-derived cells,42,43 tumor-associated macrophages,44 can-
cer-associated fibroblasts45-47, and tumor vasculature.48 To define 
the origin and composition of tumor stroma and to elucidate 
whether and when cells are recruited for stroma formation from 
systemic BM and/or nearby local sources, we developed color-
coded BM-chimeras (Fig. 2B). Longitudinal imaging for 21 d 
revealed that early during tumor formation mainly BM-derived 
stromal cells were recruited and that these cells began to acquire 
a fibroblastoid shape by day 9. Previously, we demonstrated that 
the majority (> 90%) of CD45+ cells in established MC57 tumors 
are CD11b+F4/80+ macrophages,12 and < 10% of CD11b+ cells 
are Gr1hi granulocytic cells. Non-BM-cells delineated the ves-
sels with a few of these cells interspersed throughout the stroma 
(Fig. 2B, day 21). These cells included endothelial cells,49 and 
type I collagen-producing fibroblasts (unpublished data). These 
results highlight the capacity of cancer cells to mobilize different 
sources of cells, at different times, from different compartments 
for the formation of stroma.
Entry and dissemination of adoptively transferred T cells in 
solid tumors
To characterize the course of tumor destruction following 
adoptive T cell therapy, we asked where, when, and how adop-
tively transferred tumor-specific CD8+ T cells arrived and distrib-
uted within the tumor tissue. In vitro activated 2C EYFP CD8+ 
T cells were injected intravenously into MC57-SIY-Cerulean 
tumor-bearing DsRed Rag1−/− mice. It was not until 2–3 d post 
transfer that EYFP+ 2C T cells extravasated preferentially at a few 
discrete sites (Fig. 3A and B; Video 3). When the same tumor 
was re-imaged 24 h later, many T cells had now infiltrated the 
tumor mass (Fig. 3C and D). However, T cell distribution and 
action within the tumor was not homogenous; at 96 h post-T 
cell transfer, some blue tumor areas contained hardly any T 
cells (Fig. 3C and D lower half, and 3E), whereas adjacent areas 
showed massive T cell infiltration and red “stroma-only-areas” 
(Fig. 3D upper half, and 3E).
Visualization of cell-cell interactions during T cell-mediated 
tumor destruction
We next performed high-resolution imaging to visualize cell-
cell interactions at the onset of tumor death in order to obtain 
mechanistic insights into T-cell mediated cancer elimination and 
to elucidate the role of stroma during this process. As shown in 
Figure 3F and G, Figure 2C EYFP T cells engaged with blue 
MC57-SIY-Cerulean cancer cells, forming T cell-cancer cell con-
jugates (Fig. 3F, yellow arrows). Membrane blebbing, one of the 
common features of cells undergoing programmed cell death was 
observed during CTL-mediated tumor destruction (Video 4), 
and subsequently, apoptotic blue tumor material was engulfed 
by red host stromal cells (Video 4). However, cell-cell contact 
dependent CTL-mediated cancer cell apoptosis and membrane 
blebbing typically associated with perforin-mediated lysis50 was 
an infrequent event. Thus, to evaluate the role of perforin in 
T cell-mediated tumor destruction we generated 2C T cells defi-
cient in perforin (2C Prf-−/−) and evaluated anti-tumor activity in 
vivo. Interestingly, perforin was not needed for the rejection of 
large MC57-SIY tumors, as 2C Prf−/− T cells eliminated MC57-
SIY tumors as efficiently as 2C WT T cells (Fig. 3H).
Cross-presentation of SIY antigen by CD11b+ tumor stromal 
cells has been demonstrated by the use of high-(nM) affinity 
TCR tetramers ex vivo12,13 and we hypothesized that cross-pre-
senting stromal cells might be a direct target for 2C T cells in 
vivo and eventually being killed. Thus far, the physical interac-
tion between T cells and stromal cells and direct T-cell mediated 
killing of stromal cells within the tumor microenvironment in 
vivo has never been demonstrated. We observed that initially rap-
idly migrating 2C T cells arrested upon encounter with stromal 
cells, resulting in stable interactions (Fig. 3F and G; Video 5). 
However, we did not observe apoptosis of stromal cells coinci-
dent with a T cell attachment. Even after MC57-SIY-Cerulean 
cancer cells were eliminated, round stromal cells persisted and 
T cells engaged with stromal cells forming stable interactions 
(Fig. 3I and J; Video 6). At later time points post cancer elimina-
tion, T cells displayed faster migration patterns associated with 
lower arrest coefficients, and higher mean velocities and diffu-
sion coefficients (Fig. 3J; Video 7).
T cells form long-lasting, stable, and cognate antigen-depen-
dent interactions with stromal cells resulting in the production 
and release of IFNγ
Because, contrary to our expectation, we observed T cell-stro-
mal interactions rather than killing of the stromal cells by tumor-
specific CD8+ T cells, we next focused our efforts on elucidating 
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the functional consequences of CTL-stromal interactions and 
engagements for tumor destruction. First, we confirmed antigen-
dependent stromal T cell-stromal cell interactions in a second 
tumor model Pro4L-SIY-Cerulean. Again, T cells formed long-
lasting interactions with stromal cells without subsequent apop-
tosis (Fig. 4A corresponding to Video 8); this T cell behavior was 
dependent on cognate antigen, since 2C T cells in antigen-nega-
tive Pro4L control tumors had a significantly lower arrest coeffi-
cient (0.69 vs 0.98) and significantly higher mean velocity (1.61 vs 
0.48 μm/min) (Fig. 4B-D; Video 9). Antigen-dependent stromal 
engagements were stable and long-lived as revealed by longitudi-
nal imaging over the course of several days (Fig. S4A and B). 
Similarly, antigen-dependent T cell arrest was observed in MC57-
SIY-Cerulean tumors (Fig. S4C). Importantly, imaging proce-
dures (over 2 h long) did not induce phototoxicity and did not 
decrease or damage T cell motilities (Fig. S4D).
To elucidate the effects of stromal cross-presentation on CD8+ 
T cells, we next isolated CD11b+ stromal cells from large estab-
lished antigen-positive (Ag+) MC57-SIY, or antigen-negative 
(Ag−) MC57 control tumors and co-cultured them together with 
effector 2C T cells for 24 h ex vivo. 2C T cells released high 
amounts of IFNγ when re-stimulated with stromal cells from 
Ag+ tumors, but not from Ag− tumors, and cross-presenting 
stromal cells from Ag+ MC57-SIY tumors induced significantly 
higher levels of IFNγ release than Ag+ cancer cells (Fig. 4E, left 
panel). Consistent with these data, high levels of IFNγ within 
tumor tissue was only detected in the cross-presentation-enabled 
MC57-SIY tumors, but not in the antigen-expressing but cross-
presentation-disabled MC57-Ld tumors, the latter inducing only 
marginally higher IFNγ levels than control tumors (Fig. 4E, 
right panel). In conclusion, our imaging technology allowed us to 
demonstrate that CTL engage with stromal cells (Fig. 4B) with-
out killing them, which activates CTL to release IFNγ (Fig. 4E).
Minimal, perivascular infiltration of antigen-specific T cells 
rapidly initiates vessel destruction
We next sought to visualize with our longitudinal imaging 
approach the kinetics of T cell mediated effects on tumor vascu-
lature. We imaged every 12 h the same tumor regions over several 
days after T cell transfer, and quantified 3D volume and integ-
rity of tumor vasculature by developing a novel vessel perfusion 
measurement approach (Fig. 5; Fig. S5): 1,1-dioctadecyl-3,3,3,3-
tetramethylindodicarbocyanine perchlorate (DiD)-labeled red 
blood cells (RBC) were injected into mice with established 
MC57-SIY tumors or Ag− MC57 control tumors, and tumors 
were imaged longitudinally in 3D by acquiring z-stack images, 
every 12 h over several days. Systemic injection of DiD-labeled 
RBCs is a useful and validated technique to measure blood flow 
(or absence thereof) and vascular networks, and ideal for long-
term studies due to the long half-life of labeled RBC.51 While 
we never observed T cells directly killing tumor vasculature 
and/or endothelial cells, we observed that minimal, perivascular 
infiltration of antigen-specific T cells resulted in vessel leakiness 
indicating vessel damage in Ag+ MC57-SIY tumors (Fig. 5A; 
Fig. S5A; corresponding Videos 10, 11, and 3D reconstruction 
images Video 12), but not in Ag- MC57 tumors (Fig. S5B; corre-
sponding Video 13). For all time points, maximal projections of 
z-stacks were generated (Fig. 5B), vessel volumes were calculated, 
and a novel algorithm was generated to render a “vessel perfusion 
index” as described in Materials and Methods (Fig. 5B–E). While 
perfusion indexes and 3D vessel volume remained constant over 
time in Ag− tumors, both vessel perfusion and volume dramati-
cally decreased in Ag+ MC57-SIY tumors (Fig. 5D and E). Thus, 
vessel regression began and coincided with the earliest time points 
of T cell entry in Ag+ tumors but not in Ag− tumors (Fig. 5F). 
However, while immediate vessel regression was observed upon 
T cell entry, cancer regression was observed at later time points 
(> 3 d post T cell transfer) (Figs. 3D, 5A and F; Fig. S5). These 
kinetics and observations were solely dependent on antigen-
expression by the tumor, as Ag− control tumors did not reveal 
any signs of vessel regression even at later time points (Fig. 5F).
Longitudinal real-time in vivo imaging of cancer variants 
elimination
The outgrowth of variant cancer cells is a frequent cause for 
the failure of cancer treatments in humans, including T cell ther-
apy.52-54 Our previous work has demonstrated that cancer cells that 
have lost antigen expression, or antigen-loss variants (ALV), are 
eliminated if the stroma is sensitized by antigen released from the 
cancer cells that have not lost the antigen. However, the mecha-
nism by which CD8+ T cells eliminate ALV has remained elusive. 
Two scenarios have been proposed: (1) CD8+ T cells become indis-
criminate killers and eliminate ALV by direct cell-cell engagement, 
or (2) CD8+ T cells target sensitized stromal cells resulting in indi-
rect, bystander killing of ALV. Interestingly, it was recently demon-
strated that IFNγ not only acts synaptically (i.e., toward antigenic 
target cells) but multidirectionally affecting non-antigenic bystand-
ers in vitro.55 Obviously, the kinetics of elimination in these 2 sce-
narios would be very different. In the first, Ag+ cancer cells and 
ALV would die simultaneously, whereas in the second, Ag+ bulk 
tumor would be killed by T cells first, causing sensitization of the 
stroma, and subsequently bystander death of ALV. Therefore, we 
set out to visualize and determine the kinetics and mechanism(s) 
of ALV elimination. Parental MC57 cancer cells were transduced 
to express DsRed (Fig. 6A). MC57-DsRed cells are not recognized 
by 2C T cells because they do not express the SIY or Ld antigen 
and thus mimic ALV in our model. DsRed-ALV were mixed in a 
1:20 ratio with either Ag+ MC57-SIY-Cerulean or Ag+ MC57-Ld-
Cerulean blue cancer cells. The difference between these 2 models 
is that only MC57-SIY but not MC57-Ld can sensitize stroma. The 
cancer cell mixtures were inoculated into Rag1−/−  window-bearing 
mice (Fig. 6B). As shown in Figure 6C and D (panel 1), DsRed+ 
ALV grew and were homogeneously embedded in the blue, Ag+ 
bulk tumor tissues of both, MC57-SIY-Cerulean or MC57-Ld-
Cerulean (quantified in Figure 6E, left panel). In vitro activated 
2C EYFP T cells were adoptively transferred. T cells arrived at 
the tumor site (Fig. 6C and D, panel 2), and again infiltrated the 
tumor heterogeneously (Fig. 6C and D, panel 3). While T cells 
eliminated Ag+ MC57-SIY-Cerulean and MC57-Ld-Cerulean can-
cer cells, red ALVs were not eliminated; 5 d after T cell transfer, 
ALV persisted and several “red-only” areas emerged [Figure 6C 
(panel 3, lower part) and D (panel 3, upper part)]. However, T cells 
remained in the microenvironment: while T cells were arrested in 
MC57-SIY-tumors, T cells in the microenvironment of MC57 Ld 
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tumors remained motile, showing lower arrest coefficient, higher 
average velocity and higher diffusion coefficient (Fig. 6F and 
G; Videos 14 and 15). Interestingly, while MC57-DsRed ALV 
eventually disappeared in MC57-SIY tumors, ALV in MC57-Ld 
tumors persisted [Figure 6C, D (panel 4), and E (right panel)]. 
To confirm that T cells indeed interacted with stromal cells in an 
antigen-dependent fashion, we developed a 4-color model to simul-
taneously visualize Ag+ cancer cells, ALV, stromal cells, as well as 
T cells (Fig. S6A). Again, T cells in MC57-SIY tumors engaged 
with stromal cells, in contrast to T cells in MC57-Ld tumors, and 
showed a significantly decreased velocity and higher arrest coeffi-
cient (Fig. S6D–G; Videos 16 and 17). Most importantly, ALV in 
MC57-Ld tumors grew, while ALV in MC57-SIY tumors eventu-
ally died (Fig. S6B and C). Since ALV in both models were com-
pletely eliminated in sensitized stroma of Kb/SIY tumors but not in 
Ld-tumors, we hypothesize that in this tumor model T cell-stromal 
engagements are required for the elimination and prevention of re-
growth of cancer variants.
Discussion
We developed an in vivo window imaging model to longitudi-
nally monitor the complex interplay of color-coded cancer cells, 
ALV, BM- and non-BM-derived stromal cells, tumor-specific 
CD8 T cells, as well as tumor vasculature in solid cancers. By 
overcoming the limitations of previous approaches using termi-
nal intravital imaging of surgically exposed tumors, we captured 
for the first time in real-time and high resolution, the dynamic, 
immune-mediated sequence of events within a given tumor over 
hours, days, and even weeks after adoptive T cell transfer. The 
powerful, technological advance is the ability to longitudinally 
monitor the same area, and to image how events unfold within 
precisely the same region over time. In contrast, non-longitudinal 
intravital imaging can only capture single end points and does not 
allow revisiting the same area at later time points. Even when large 
numbers of animals for each different time point are being used to 
compensate for the variability of tumor regions chosen for analy-
sis, any resulting sequences of events are reconstructed. Here, we 
found that vessel regression begins and coincides with the earliest 
time points of T cell entry from the blood stream into the tumor 
(Fig. 5). This may explain the enigma why solid tumors “melt” 
from the inside following successful T cell attack, although only 
few T cells deeply infiltrate into the tumor early after T cell trans-
fer.56 Importantly, the use of long-term tumor window implant 
device eliminated the necessity to surgically expose the tumor tis-
sue just prior imaging, thereby eliminating potential confounding 
influences due to acute tissue injury and blood vessel destruction, 
and associated immediate inflammatory effects.28-30
Our imaging approach also allowed us to develop quantita-
tive contextual analyses of T cell interactions with cancer cells 
and stroma, and design novel algorithms for the quantitative 
assessment of vessel integrity and perfusion over time after T cell 
therapy. These analyses revealed that perforin-mediated direct 
CTL-killing was, contrary to our expectation, not the primary 
mechanism leading to cancer destruction (Fig. 3H). Furthermore, 
stromal cells cross-presenting tumor-antigen are not a target for 
perforin-mediated destruction but serve as a prolonged and highly 
effective stimulus for antigen-specific T cells resulting in the pro-
duction and release of high amounts of cytokines (IFNγ) within 
tumors, which has been shown to be required in some models for 
the elimination of tumors, including antigen loss variants.11,19,57,58 
Tumor relapse of cancer variants often occurs after initial T cell-
mediated tumor destruction11,12,59 and usually resumes from the 
tumor margin surviving after central necrosis. Even in the face 
of a potential “field effect” of vessel destruction, causing some 
bystander cancer cell death, including ALV, we found that when 
the tumor bulk was being destroyed, ALV may survive and remain 
within the microenvironment. Tumor-specific CD8+ T cells in 
Kb/SIY tumors interacted with antigen-sensitized stromal cells. 
Subsequently, this interaction triggered the production and release 
of high levels of IFNγ (Fig. 4E). In agreement with these results, we 
found higher amounts of IFNγ in vivo in stroma of Kb/SIY tumors 
than in the stroma of Ld- or control tumors (Fig. 4E). While the 
cytokine release is clearly dependent on and mediated by the for-
mation of conjugates between T cells and cells presenting the anti-
gen, the effect of the released cytokines (cytokine-mediated killing 
of target cells) does not require conjugate formation. While perfo-
rin, not needed in our model (Fig. 3H), depends on effector-target 
conjugates for achieving cell death, IFNγ- and TNFα-dependent 
killing can be mediated without direct target contact,60 and can 
act multidirectionally affecting non-antigenic bystanders.55 Since 
ALV were eliminated in sensitized stroma of Kb/SIY tumors but 
not in Ld-tumors, we propose that stromal cross-presentation, 
T cell-stromal engagements, and subsequent high cytokine release 
in this model are helping the elimination of ALV and prevention 
of re-growth of cancer variants. Identifying precisely how cyto-
kines such as IFNγ and TNF released by T cells contribute to ALV 
elimination, prevention of ALV re-growth (e.g., cytokine-mediated 
cytotoxicity, IFNγ-induced Fas/FasL-dependent apoptosis,59,61 or 
IFNγ-mediated prevention of tumor vasculature regeneration), 
and vessel destruction, or if other factors could potentially override 
the requirement of stromal cross-presentation for tumor elimina-
tion and/or cancer variants, will be the focus of future studies.
In conclusion, the ability to visualize distinct immune, stroma 
and cancer cell subsets in distinct compartments of tumors and 
to longitudinally follow their fate in vivo will help to elucidate 
the underlying mechanism(s) responsible for success or failure 
of anti-cancer immunotherapies or other anti-cancer therapeutic 
approaches.
Materials and Methods
Mice and Cell lines
C57Bl/6 Rag1−/− mice were purchased from The Jackson 
Laboratory; Tg(ACTB-DsRed*MST)1Nagy/J mice were pur-
chased from The Jackson Laboratory and crossed to C57BL/6 
Rag-1 KO mice to obtain DsRed Rag-1 KO mice. 2C TCR Rag 
KO mice were provided by J Chen (Massachusetts Institute of 
Technology). To generate 2CEYFP mice, 2C TCR mice were 
crossed to 129-Tg(ACTB-EYFP)7AC5Nagy/J, obtained from 
The Jackson Laboratory. 2C × EYFP mice were backcrossed to 
C57BL/6 for 7 generations. 2C × EGFP mice were generated 
www.landesbioscience.com OncoImmunology e26677-11
by crossing 2C TCR to EGFP transgenic mice (obtained from 
Jackson Laboratory). Over 95% of CD8-EYFP T cells expressed 
the Vβ8.1 8.2-chain. All mice were bred and maintained in a spe-
cific pathogen-free barrier facility at The University of Chicago 
according to the Institutional Animal Care and Use Committee 
(IACUC) guidelines. To generate colored bone-marrow chime-
ras, EYFP Rag1−/− mice were lethally irradiated and reconsti-
tuted 24 h later with 5 × 106 bone-marrow cells from DsRed 
Rag1−/− mice. Imaging experiments were initially performed at 
the Vanderbilt University Cell Imaging Shared Resource (CISR) 
and subsequently at The University of Chicago Light Microscopy 
Core Facility. For experiments done at Vanderbilt University, 
mice were shipped via special airplane carriers from University of 
Chicago and maintained in a special mouse facility at Vanderbilt 
University. All animal experiments were approved by the IACUC 
of Vanderbilt University and The University of Chicago. MC57G 
was provided by P Ohashi (University of Toronto), with permis-
sion of H Hengartner (University Hospital Zurich). The murine 
fibrosarcoma cell line Pro4L was derived from the C3H/HeN 
mouse undifferentiated spindle cell cancer 1591-PRO4L and has 
been described preciously.6
Antibodies, plasmids, and retroviral vectors
PE-anti-mouse H-2Kb (AF6–88.5), PE-anti-mouse Vß8.1, 
8.2 TCR (MR5–2), and anti-mouse CD8a (53–6.7) antibodies 
used for flow cytometry were obtained from BD PharMingen. 
The anti-Ld antibody (30–5-7) was obtained from D Sachs 
(Massachusetts General Hospital). The retroviral vector pMFG 
was obtained from RC Mulligan and retroviral infections 
were performed as described.62 The plasmid pDsRedT1-N1 
was obtained from Clontech. The plasmid mCerulean-C1 was 
obtained from DW Piston, Vanderbilt University and used for 
subsequent cloning to generate the retroviral vectors pMFG-
Cerulean and pMFG (SIY)
3
-Cerulean.
Generation of pMFG Cerulean and pMFG (SIY)
3
-Cerulean 
vectors
To generate pMFG-Cerulean, Cerulean was amplified from 
mCerulean-C1 using the primers 5′ - GCG CCA TGG TGA 
GCA AGG GCG AGG AGC - 3′ and 5′ - GCG GAT CCT 
TAC TTG TAC AGC TCG TCC ATG CCG - 3′, digested 
with NcoI and BamHI (New England Biolabs), and ligated into 
pMFG digested with NcoI/BamHI. To generate pMFG (SIY)
3
-
Cerulean, the minigene SIYRYYGL-AAY trimer was cut from 
pLEGFP-SIY with NcoI and ligated into pMFG- Cerulean.
Generation of tumor cell lines
MC57, MC57-Ld, and Pro4L were retrovirally infected to 
express the fluorescent proteins Cerulean or (SIY)
3
-Cerulean 
respectively as described 39. After infection, cell lines MC57-
(SIY)
3
-Cerulean, Pro4L-(SIY)
3
-Cerulean, MC57-Ld-Cerulean 
were sorted multiple times by FACS for high expression of 
Cerulean. To obtain the cell line MC57-DsRed, MC57 was 
transfected with pDsRedT1-N1 (Clontech) using Ca-phosphate 
transfection. MC57-DsRed cells were FACS-sorted for high 
DsRed protein expression.
In vitro T cell activation and adoptive transfer of 2C T cells
For the adoptive transfer of activated 2C-EYFP or 2C-EGFP 
CD8+ T cells, (NH
4
)Cl–treated splenocytes from 2C × EYFP 
or 2C × EGFP mice were stimulated in vitro with IL-2 (8U/ml) 
(in some experiments without IL-2) and SIYRYYGL peptide 
(7.5 μg/ml) for 3–4 d at a concentration of 4 × 106 cells/ml. 
Approximately 5 × 106 activated T cells were injected intrave-
nously into the retro-orbital plexus. H Auer and S Meredith 
(University of Chicago) synthesized the 2C-recognized peptide 
SIYRYYGL.
Flow cytometric analysis
Flow cytometric analysis was performed using FACSCalibur, 
FACScan, and DakoCytomation CyanADP and analyzed with 
FlowJo software (BD Biosciences). Tumor cell lines were sorted 
using DakoCytomation MoFlo HTS and BD FACS Aria.
Window implantation and cancer cell injection
The in vivo tumor window model was performed as the win-
dow chamber model previously described41,63 with some modifi-
cations. In brief, before surgery, hair was removed from the back 
of the mouse and skin was surface treated with iodine solution. 
For initial experiments, mice were anesthetized by administering 
intraperitoneally a mixture of ketamin and xylazine, later inhaled 
isoflurane was used exclusively. A circular hole of 1 cm diameter 
was dissected in one side of the skin surface of the dorsal skin 
flap by removing skin and fascial plane, leaving the opposite skin 
layer and its fascial plane with associated vasculature. The win-
dow frame was then implanted as previously described.41 Cancer 
cells (re-suspended in 20–30 μl 1 × PBS) were injected at 3–5 
different sites in between the fascia and dermis of the rear skin 
layer. The window frame was sealed with only 1 glass coverslip 
and clamped to the window frame with a C-ring. Window frames 
were tightened via 3 screws and sutured additionally. Titanium 
window frames were purchased from and specially modified by 
APJ Trading Co. Inc. All procedures were performed using sterile 
material and equipments.
Confocal microscopy
Window chamber mice were anesthetized by administering 
a mixture of ketamine and xylazine intraperitoneally; isoflurane 
was used in later experiments. The window was fastened to the 
main stage of the microscope using a custom-made holder. (For 
experiments performed at University of Chicago: a stage insert 
was custom-built by the engineering team at the University of 
Chicago Engineering Center (UCEC) to hold the anesthetized 
animal in the same position on the microscope. The stage insert 
fixed mouse and implanted window always in the same position 
by indexing the 3 screws (asymmetric triangle) that are used to 
hold the window frame plates together. Mechanical clamps were 
holding the imaging window frame to the stage insert. A motor-
ized microscope XY scanning stage and Leica LAS-AF software 
allowed recording individual 3-dimensional positions per field-
of-view and returning to them later with high precision (stated 
accuracy +/− 3μm; reproducibility < 1.0μm). Using blood ves-
sels as “landmarks,” same vessels could be located within 50μm 
when returning on the same day, or within 100μm on the next 
day). Body temperature was maintained by placing every 10 
min a warm (37 °C), water filled glove on the mouse’s body. 
Confocal images were captured with a Zeiss LSM 510 Confocal 
Microscope System (Vanderbilt), or a Leica SP5 II TCS Tandem 
scanner 2-photon spectral confocal with 4 × and 20 × /0.45 LWD 
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IR objectives from Olympus (University of Chicago). A X-Y 
motorized stage was used for multiple point visiting during imag-
ing experiments. For visualization of the tumor vasculature, mice 
were injected with 2.000.000 MW anionic, fluorescein-conju-
gated dextran (Molecular Probes), or 1,1-dioctadecyl-3,3,3,3-
tetramethylindodicarbocyanine perchlorate (DiD)-labeled 
red blood cells (RBC).64 Briefly, RBC were obtained from the 
peripheral blood of C57Bl/6 Rag1−/− mice and stained with DiD 
(Invitrogen) for 30 min at 37 °C. After 3 washes with PBS, 
DiD-labeled RBC were injected intravenously. Absorption and 
fluorescence emission maxima of DiD are 644nm and 665nm 
respectively. The optical penetration of tissue ranged between 
90–500μm with the average of 120–150μm.
Data analysis
Initial digital image processing was performed using Zeiss LSM 
browser and Leica LAS-AF Lite and selected images were further 
analyzed using ImagePro 6.3 (MediaCybernetics), Fiji (NIH), 
and SlideBook 4 software (Intelligent imaging Innovations). 
Time-lapse recordings were corrected for drift based on landmark 
features and T cell motility was tracked and quantified using 
Imaris 7.5 software (Bitplane). T cell diffusion coefficient (D) was 
calculated as D = L2/t, with L being the cell track displacement 
length (μm) and t the track duration in minutes. Arrest coeffi-
cient was calculated as the fraction of time that T cell velocity was 
less than 3 μm/min. The long-term arrest was defined as when a 
cell centroid did not displace further than 1 half of the cell diam-
eter (5 μm) for at least 15 min; in shorter movies, the entire length 
of the movie was considered.. For Figure 5F: images displayed in 
Figure 5B were analyzed using Fiji to determine the area occupied 
by cerulean or EYFP expressing cells, as well as by vessels in maxi-
mum intensity projections of z-stacks .
Contextual analysis of T cell interaction targets
T cell interactions were analyzed using the Leica Application 
Suite version 1.7.0 build 1240 (Leica Microsystems), Imaris 7.5 
(Bitplane Inc.) and Slidebook software (Intelligent Imaging 
Innovations Inc.). An interaction was defined as cell immobili-
zation for at least 15 min. To detect the sites of T cell immobi-
lization in an unbiased manner, raw 3-D time-lapse recordings 
were first corrected for drift, if any, then threshold and binarized. 
Next, the binarized time-lapse data sets were processed to gener-
ate 2 types of time projection images: the average intensity time 
projection (AITP) and the maximum intensity time projection 
(MITP). The AITP image has the important property that pixel 
intensities represent the duration of cell persistence in the area, 
and the MITP image represents all places visited by cells during 
intravital motility recording. To detect the sites of cell persistence 
for 15 min or longer in a 60 min long recording, the AITP image 
was thresholded at the corresponding pixel intensity value. The 
thresholded AITP image was then merged with the MITP image 
into a single 2-color image such that the areas of overlap rep-
resented the areas of 15 min long T cell persistence in relation 
to all T cell-visited areas. The image representing T cell persis-
tence sites was then overlaid over the images of other fluorescence 
channels that were co-visualized during the intravital recording, 
and the cell persistence sites were categorized based on the type 
of immediately adjacent neighboring cells.
Analysis of vessel volume and vessel perfusion index
The index of vessel perfusion was designed based on the 
observation that movements of brightly-labeled RBCs during 
collection of the 3D time series data become blurred due to 
the blood flow, resulting in a low frequency components in the 
XYZ Fourier space and high frequency components in the time 
domain. In contrast, the lack of blood flow results in stationary, 
discernible RBCs giving rise to higher frequency components in 
the XYZ Fourier space but decreasing the high frequency com-
ponents in the time domain, which is quantifiable as low val-
ues of time-domain standard deviation (td-StDev). Maximal 
projections of z-stacks of DiD-labeled RBC were generated to 
document vessel morphology, and the functional vessel volume 
within those 3-D stacks was calculated as the space occupied by 
DiD-RBC using the ImageJ “3D Object Counter” plugin. When 
vessels showed compromised/impaired integrity (as evidenced by 
lack of blood flow in the 3D stacks viewed as a temporal series), 
a value of 0 was manually assigned. Subsequently, an algorithm 
was designed by using a statistical quantification method to ren-
der a “vessel perfusion index” (VPI) from the td-StDev of DiD-
intensities throughout the entire set of z-stacks. An ImageJ macro 
was created that automatically calculated pairwise td-StDev of 
per-pixel intensity changes in 3D stack images. Pairwise com-
parisons limited the intensity changes to RBC movements and 
lessened contributions of changes in background structure. The 
mean td-StDev was normalized to the number of frames and cor-
rected by subtracting the image median to reveal RBC intensity 
changes. The resulting value is what we called VPI. VPI is an 
indirect measure of vessel integrity: high td-StDev in the DiD 
channel indicates fast blood flow and consequently good vessel 
integrity; low td-StDev results from static DiD-RBC reflecting 
impaired vessel integrity. 3D vessel reconstruction/rotation vid-
eos were done using Imaris.
Statistical Analyses
Statistical analysis was performed using GraphPad Prism 
5.03, typically using the Mann Whithey test. Measurement 
differences resulting in P values of 0.05 or less were considered 
as statistically significant and are referred to as such in the text. 
All error bars represent standard deviations, unless indicated as 
standard errors.
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